Health Sciences Trust
Fund
JEHSX
Price as of:
$23.69
- $0.08
- 0.34%
Primary Theme
fund company
Name
As of 04/17/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
1.0%
1 yr return
-2.3%
3 Yr Avg Return
-1.8%
5 Yr Avg Return
8.1%
Net Assets
$263 M
Holdings in Top 10
42.3%
52 WEEK LOW AND HIGH
$23.8
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 1.06%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 29.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$0
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 04/17/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
JEHSX - Profile
Distributions
- YTD Total Return 1.0%
- 3 Yr Annualized Total Return -1.8%
- 5 Yr Annualized Total Return 8.1%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.47%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameHealth Sciences Trust
-
Fund Family NameJohn Hancock Group of Funds
-
Inception DateApr 30, 2001
-
Shares OutstandingN/A
-
Share ClassOther
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerZiad Bakri
Fund Description
Under normal market conditions, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in common stocks of companies engaged, at the time of investment, in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively, “health sciences”). (The fund will provide written notice to shareholders at least 60 days prior to a change in its 80% investment policy.) While the fund may invest in companies of any size, the majority of its assets are expected to be invested in large- and mid-cap companies.The subadvisor’s portfolio managers divide the health sciences sector into four main areas: pharmaceutical companies, health care services companies, medical products and devices providers, and biotechnology firms. Their allocation among these four areas will vary depending on the relative potential within each area and the outlook for the overall health sciences sector. While most assets will be invested in U.S. common stocks, the fund may purchase other securities, including foreign securities, in keeping with its investment objective.The fund concentrates its investments (invests more than 25% of its total assets) in securities of companies in the health sciences sector, a comparatively narrow segment of the economy, and therefore may experience greater volatility than funds investing in a broader range of industries.In managing the fund, the subadvisor uses a fundamental, bottom-up analysis that seeks to identify high quality companies and the most compelling investment opportunities. In general, the fund will follow a growth investment strategy, seeking companies whose earnings are expected to grow faster than inflation and the economy in general. When stock valuations seem unusually high, however, a “value” approach, which gives preference to seemingly undervalued companies, may also be emphasized.The fund may invest up to 35% of its total assets in foreign securities (including emerging market securities) and may have exposure to foreign currencies through its investment in these securities, its direct holdings of foreign currencies or through its use of foreign currency exchange contracts for the purchase or sale of a fixed quantity of a foreign currency at a future date.In pursuing its investment objective, the fund’s management has the discretion to purchase some securities that do not meet its normal investment criteria, as described above, when it perceives an opportunity for substantial appreciation. These situations might arise when the fund’s management believes a security could increase in value for a variety of reasons including a change in management, an extraordinary corporate event, or a new product introduction or innovation or a favorable competitive development.The fund may sell securities for a variety of reasons including to realize gains, limit losses or redeploy assets into more promising opportunities.Use of Hedging and Other Strategic Transactions. The fund is authorized to use all of the various investment strategies referred to under “Additional Information About the Funds’ Principal Risks — Hedging, derivatives and other strategic transactions risk” including entering into option transactions.
Read More
JEHSX - Performance
Return Ranking - Trailing
| Period | JEHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 1.0% | -28.1% | 11.7% | 57.06% |
| 1 Yr | -2.3% | -28.8% | 21.4% | 79.75% |
| 3 Yr | -1.8%* | -35.6% | 11.4% | 67.95% |
| 5 Yr | 8.1%* | -7.0% | 14.7% | 67.15% |
| 10 Yr | 8.9%* | 0.2% | 13.6% | 59.81% |
* Annualized
Return Ranking - Calendar
| Period | JEHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -1.6% | -12.6% | 19.0% | 76.07% |
| 2022 | -23.8% | -53.9% | 3.2% | 88.46% |
| 2021 | 0.7% | -39.6% | 24.2% | 48.08% |
| 2020 | 14.3% | -13.6% | 178.2% | 47.02% |
| 2019 | 18.8% | 3.8% | 63.8% | 68.15% |
Total Return Ranking - Trailing
| Period | JEHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 1.0% | -28.1% | 11.7% | 57.06% |
| 1 Yr | -2.3% | -28.8% | 21.4% | 79.75% |
| 3 Yr | -1.8%* | -35.6% | 11.4% | 67.95% |
| 5 Yr | 8.1%* | -7.0% | 14.7% | 67.15% |
| 10 Yr | 8.9%* | 0.2% | 13.6% | 59.81% |
* Annualized
Total Return Ranking - Calendar
| Period | JEHSX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -1.6% | -12.6% | 19.0% | 85.28% |
| 2022 | -13.1% | -53.9% | 3.7% | 69.87% |
| 2021 | 11.2% | -33.9% | 26.0% | 41.03% |
| 2020 | 27.2% | -0.7% | 180.6% | 36.42% |
| 2019 | 28.7% | 4.6% | 63.8% | 39.26% |
NAV & Total Return History
JEHSX - Holdings
Concentration Analysis
| JEHSX | Category Low | Category High | JEHSX % Rank | |
|---|---|---|---|---|
| Net Assets | 263 M | 7.41 M | 47.2 B | 61.96% |
| Number of Holdings | 188 | 23 | 413 | 6.75% |
| Net Assets in Top 10 | 111 M | 2.19 M | 20.5 B | 62.58% |
| Weighting of Top 10 | 42.35% | 18.1% | 77.0% | 72.39% |
Top 10 Holdings
- UNITEDHEALTH GROUP INC COMMON STOCK USD.01 8.04%
- ELI LILLY and CO COMMON STOCK 8.00%
- THERMO FISHER SCIENTIFIC INC COMMON STOCK USD1.0 4.72%
- INTUITIVE SURGICAL INC COMMON STOCK USD.001 3.80%
- ELEVANCE HEALTH INC COMMON STOCK USD.01 3.52%
- MERCK and CO INC COMMON STOCK USD.5 3.50%
- STRYKER CORP COMMON STOCK USD.1 3.25%
- DANAHER CORP COMMON STOCK USD.01 2.78%
- VERTEX PHARMACEUTICALS INC COMMON STOCK USD.01 2.72%
- ASTRAZENECA PLC ADR 1.99%
Asset Allocation
| Weighting | Return Low | Return High | JEHSX % Rank | |
|---|---|---|---|---|
| Stocks | 97.23% | 87.17% | 106.13% | 67.48% |
| Cash | 2.32% | 0.00% | 32.99% | 50.31% |
| Preferred Stocks | 0.45% | 0.00% | 7.86% | 24.54% |
| Other | 0.00% | -22.99% | 17.73% | 84.05% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 81.01% |
| Bonds | 0.00% | 0.00% | 12.39% | 82.82% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | JEHSX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.40% | 59.26% | 100.00% | 86.08% |
| Basic Materials | 0.91% | 0.00% | 7.16% | 8.86% |
| Industrials | 0.34% | 0.00% | 7.02% | 2.53% |
| Financial Services | 0.28% | 0.00% | 1.60% | 11.39% |
| Technology | 0.07% | 0.00% | 22.69% | 5.06% |
| Utilities | 0.00% | 0.00% | 0.00% | 79.75% |
| Real Estate | 0.00% | 0.00% | 5.89% | 81.65% |
| Energy | 0.00% | 0.00% | 0.00% | 79.75% |
| Communication Services | 0.00% | 0.00% | 9.11% | 79.75% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 83.54% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 81.01% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | JEHSX % Rank | |
|---|---|---|---|---|
| US | 96.25% | 66.21% | 104.41% | 38.04% |
| Non US | 0.98% | 0.00% | 28.58% | 53.37% |
JEHSX - Expenses
Operational Fees
| JEHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.06% | 0.08% | 4.28% | 52.15% |
| Management Fee | 0.92% | 0.03% | 1.25% | 89.57% |
| 12b-1 Fee | 0.05% | 0.00% | 1.00% | 16.67% |
| Administrative Fee | 0.25% | 0.03% | 0.25% | 100.00% |
Sales Fees
| JEHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| JEHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| JEHSX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 29.00% | 0.00% | 238.00% | 21.74% |
JEHSX - Distributions
Dividend Yield Analysis
| JEHSX | Category Low | Category High | JEHSX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.36% | 84.66% |
Dividend Distribution Analysis
| JEHSX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Quarterly | Annual |
Net Income Ratio Analysis
| JEHSX | Category Low | Category High | JEHSX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.47% | -2.54% | 1.85% | 67.95% |
Capital Gain Distribution Analysis
| JEHSX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
JEHSX - Fund Manager Analysis
Managers
Ziad Bakri
Start Date
Tenure
Tenure Rank
Apr 01, 2016
6.17
6.2%
Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.84 | 0.25 |